FDA approves label updates for Breyanzi and Abecma to reduce certain patient monitoring requirements and removes the Risk Evaluation and Mitigation Strategy (REMS) programs July 1, 2025
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies June 3, 2025
Lumanity and Parker Institute for Cancer Immunotherapy (PICI) Announce Partnership to Accelerate Immunotherapy Innovation June 3, 2025
Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer May 27, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline May 21, 2025
AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline May 21, 2025
GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 21, 2025
FDA lifts the clinical hold on IND applications for the EBVALLO™ (tabelecleucel) program May 13, 2025
Strategic Pipeline Prioritization Announced with Focus on CB-010 and CB-011 Oncology Programs April 30, 2025
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies April 30, 2025
Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast April 30, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 8, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 2, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing February 11, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors January 15, 2025
Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL January 7, 2025
